Search

The role of inflammation in the pathophysiology of DMO

Diabetic macular oedema (DMO) is a major cause of visual loss in diabetes, with a complex multifactorial pathogenesis. In the UK alone it is estimated that there are nearly 2.5 million diabetic patients aged over 12 years. Approximately 65,000 of...

Designing ophthalmology services - Part 1: How do we address the queues in a clinic?

This first of a three-part series shows how systems engineering can be used to correctly diagnose and address the causes of delays in a clinic. The second article, which will be featured in the April/May 2020 issue, describes how to...

Designing ophthalmology services Part 3: How do we address the queues post‑COVID-19?

Part 1 of this series available herePart 2 of this series available here There is going to be enormous demand on ophthalmology services as they start to welcome patients back. The authors explain how modelling can help make the most...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Specialist high-street eye clinics for managing patients with retinal disorders can enhance care standards

The author examines the successful introduction of community-based retinal clinic services by Manchester University NHS Foundation Trust. Dr Sajjad Mahmood, Consultant Ophthalmologist, MREH, shares experience of establishing community-based medical retina clinic services. Sight loss from age-related macular degeneration (AMD), cataract,...